1. 2021 National Distributor & J&J Agreements (“Wave One”)
- A bipartisan coalition of state attorneys general reached agreements in July 2021 with:
- Distributors: McKesson, Cardinal Health, AmerisourceBergen (also known as Cencora)
- Manufacturer: Janssen Pharmaceuticals (part of Johnson & Johnson, J&J)
- These deals totaled approximately $26 billion:
- Distributors: up to $21 billion over 18 years
- J&J: up to $5 billion over up to 9 years
- States and local governments that opted in would receive funding—or, in some cases, product support—for opioid abatement, with at least 85% of funds earmarked for prevention, treatment, and recovery efforts. Wikipedia National Opioid Settlement
2. 2022–2023 Add-on Agreements (“Wave Two”)
- Additional settlement agreements were finalized with:
- Pharmacy Chains: CVS, Walgreens, Walmart
- Manufacturers: Allergan and Teva
- Anticipated payouts (assuming broad participation):
- Teva: up to $3.34 billion + Narcan product donations or cash alternatives
- Allergan: up to $2.02 billion
- CVS: up to $4.90 billion
- Walgreens: up to $5.52 billion
- Walmart: up to $2.74 billion in 2023, across 6 years
- Like the Wave One settlements, at least 85% of the funds must be used for abatement; additionally, these agreements include injunctive measures and oversight tools (e.g., increased monitoring, shipment-tracking “clearinghouse” systems) National Opioid Settlement National Opioids Settlement.
Altogether, these “national” settlement programs are shaping up to deliver tens of billions of dollars over time to communities across the U.S.
Notable Additional Settlements & Developments
Purdue Pharma & the Sackler Family
- A highly publicized settlement attempt to shield the Sackler family was blocked by the U.S. Supreme Court in June 2024. The court held that the bankruptcy plan couldn’t release claims against non-debtors without consent. New York Post Wikipedia
- Following extended negotiations, a new $7.4 billion settlement was reached in January 2025, in principle with 15 states (later supported by all state and territory attorneys general). The agreement:
- Requires the Sackler family to relinquish control of Purdue Pharma
- Allocates around
$800–850 millionspecifically to victims and survivors - Allows non-settling parties to still pursue litigation
- This deal is pending approval by a U.S. bankruptcy judge. ReutersTimes UnionTexas Attorney General Wikipedia
Viatris Settlement
- In April 2025, Viatris agreed to pay up to $335 million over nine years to resolve opioid-related claims, contributing approximately $27.5–40 million per year to support state and local initiatives. Reuters
Walgreens DOJ Settlement
- In April 2025, Walgreens settled with the U.S. Department of Justice for up to $350 million over allegations of illegally filling opioid prescriptions under the False Claims Act. The agreement includes a $50 million contingency if corporate changes transpire before 2032. Walgreens denies liability. The Guardian
Summary at a Glance
| Timeframe | Major Parties Involved | Settlement Scope & Impact |
|---|---|---|
| 2021 | Distributors + J&J | ~$26 b over years ⇒ funds + product + reform measures |
| 2022–2023 | CVS, Walgreens, Walmart, Allergan, Teva | Additional multi-billion payouts + oversight tools |
| January 2025 | Purdue/Sacklers | $7.4 b w/ victim allocation, structural changes to Purdue |
| April 2025 | Viatris & Walgreens | $335 m from Viatris; $350 m DOJ settlement with Walgreens |
Across these agreements, the nationwide total is well into the $50+ billion range, targeting relief funding, legal accountability, and industry reforms to curb future harm.
💰 Profits vs. Settlements
- Profits dwarf payouts:
- Purdue Pharma (Sacklers) made an estimated $10–13 billion from OxyContin alone between the late 1990s and 2019. Even after the new $7.4 billion settlement, the Sackler family will retain billions and won’t face criminal charges.
- Distributors (McKesson, Cardinal Health, AmerisourceBergen) generated hundreds of billions in opioid sales revenue. McKesson alone brought in $231 billion in total revenue in 2023—the $21 billion settlement across 18 years looks small in comparison.
- Pharmacy chains (CVS, Walgreens, Walmart) each had annual revenues topping $100 billion, meaning their multi-billion settlements amount to a few months’ profits.
⚖️ Why Settlements Still Look “Small”
- Spread-out payments
- Most settlements are structured over 9–18 years. That reduces the immediate burden and makes the headline figures look larger than the real annual cost.
- Tax benefits
- Some companies may classify settlement payouts as business expenses, reducing their tax liability.
- No admission of wrongdoing
- Many settlements explicitly allow corporations to deny liability. That preserves reputation and shields executives from criminal accountability.
- Legal shield
- Settlements often prevent future lawsuits from state and local governments, essentially capping corporate liability.
🔍 Critics’ View
- Many advocacy groups, families of overdose victims, and even some state attorneys general argue that these companies got off cheaply.
- The core concern: the settlements don’t match the scale of the harm — over 600,000 deaths linked to opioids since 1999 — nor the scale of corporate profits.
✅ The Other Side
- Settlement advocates argue that without these deals, litigation could drag on for decades, delaying urgently needed funding for addiction treatment and prevention.
- The funds, even if smaller than profits, are earmarked for community programs—something that wouldn’t happen if companies just paid damages into the general treasury.
Big picture table
| Company/Owners | Settlement commitment (national programs) | Recent profit / withdrawals (context) | Quick take |
|---|---|---|---|
| Sackler family / Purdue Pharma | $7.4B (proposed 2025 plan: $6.5B from Sacklers + ~$0.9B from Purdue) | >$10B withdrawn by Sacklers from Purdue (2008–2018) | Even if approved, payout < historical withdrawals. Reuters PMC |
| McKesson (distributor) | $7.9B over 18 yrs (part of $21B distributor deal) | $3.00B net income FY2024 | Annual profit ≈ 38% of its entire 18-yr commitment. McKesson MacroTrends |
| Cardinal Health (distributor) | $6.4B over 18 yrs | $0.85B net income FY2024 | One year of profit covers ~13% of the 18-yr bill. McKessonMacroTrends |
| AmerisourceBergen → Cencora (distributor) | $6.4B over 18 yrs | $1.51B net income FY2024 | ~24% of the 18-yr obligation equals one year’s profit. McKesson MacroTrends |
| Johnson & Johnson (Janssen) | Up to $5B | $14.07B net income 2024 | One recent year’s profit ≈ 3× the total payout. National Opioid Settlement JNJ.com MacroTrends |
| Teva | Up to $3.34B cash + $1.2B Narcan (or $240M cash) | $2.86B non-GAAP net income 2024 (company metric) | One strong year of (non-GAAP) profit ≈ the cash portion. National Opioid SettlementTeva Pharmaceuticals |
| Allergan (now AbbVie unit) | Up to ~$2.0–$2.37B (multi-state) | Now part of AbbVie | Legacy Allergan settlement sits within AbbVie scale. National Opioid Settlement California DOJ |
| CVS | Up to $4.9B over 10 yrs | $1.64B GAAP net income in Q4’24; 2024 revenue $372.8B (scale) | Sizeable, but small relative to enterprise scale. CVS HealthQ4 Capital |
| Walgreens | Up to $5.52B over 15 yrs | –$8.64B GAAP net income FY2024 (impairments drove loss) | Payouts are spread over many years; results currently depressed. National Opioid Settlement MacroTrends |
| Walmart | Up to $2.74B (compressed schedule, ≤6 yrs) | $16.3B net income FY2024 | One year’s profit ≈ 6× its total commitment. National Opioid Settlement Walmart Inc. |
Notes on interpretation
- Multi-year structure makes the sticker price look bigger than the annual cost to companies (e.g., 10–18 year payment schedules). National Opioid Settlement
- The Purdue/Sackler case is unusual: comparisons are often made to owner withdrawals rather than corporate profit, because Purdue is in bankruptcy and the Sacklers are private owners. PMC
- For manufacturers like Teva, companies emphasize non-GAAP (adjusted) earnings; I included Teva’s own widely reported non-GAAP number for 2024 to give a sense of scale. Teva Pharmaceuticals
What this shows (the short version)
- For several public companies, one solid profit year (or even a fraction of it) can match or exceed their entire multi-year settlement tab—which supports your point that the settlements, while huge for communities, don’t necessarily bite deeply into corporate economics. National Opioid Settlement
- In the Purdue/Sackler case, the proposed payout is less than historic family withdrawals, further fueling the “profits > penalties” criticism. Reuters PMC
